AU2004210650C1 - Method of employing elevation of marinobufagenin in determining the presence of preeclampsia and related apparatus - Google Patents
Method of employing elevation of marinobufagenin in determining the presence of preeclampsia and related apparatus Download PDFInfo
- Publication number
- AU2004210650C1 AU2004210650C1 AU2004210650A AU2004210650A AU2004210650C1 AU 2004210650 C1 AU2004210650 C1 AU 2004210650C1 AU 2004210650 A AU2004210650 A AU 2004210650A AU 2004210650 A AU2004210650 A AU 2004210650A AU 2004210650 C1 AU2004210650 C1 AU 2004210650C1
- Authority
- AU
- Australia
- Prior art keywords
- marinobufagenin
- preeclampsia
- patient
- elevation
- range
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- FRYICJTUIXEEGK-UHFFFAOYSA-N 5beta-hydroxyldesacetylcinobufagin Natural products CC12CCC(C3(CCC(O)CC3(O)CC3)C)C3C11OC1C(O)C2C=1C=CC(=O)OC=1 FRYICJTUIXEEGK-UHFFFAOYSA-N 0.000 title claims description 47
- JMNQTHQLNRILMH-OBBGIPBRSA-N marinobufagenin Chemical compound C=1([C@H]2C[C@H]3O[C@@]43[C@H]3[C@@H]([C@]5(CC[C@H](O)C[C@@]5(O)CC3)C)CC[C@@]42C)C=CC(=O)OC=1 JMNQTHQLNRILMH-OBBGIPBRSA-N 0.000 title claims description 47
- 201000011461 pre-eclampsia Diseases 0.000 title claims description 45
- 238000000034 method Methods 0.000 title claims description 23
- 206010020772 Hypertension Diseases 0.000 claims description 17
- 210000002700 urine Anatomy 0.000 claims description 15
- 238000011282 treatment Methods 0.000 claims description 6
- CJCSPKMFHVPWAR-JTQLQIEISA-N alpha-methyl-L-dopa Chemical compound OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 CJCSPKMFHVPWAR-JTQLQIEISA-N 0.000 claims description 4
- 229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 3
- 206010047139 Vasoconstriction Diseases 0.000 claims description 3
- 239000011777 magnesium Substances 0.000 claims description 3
- 229910052749 magnesium Inorganic materials 0.000 claims description 3
- 230000025033 vasoconstriction Effects 0.000 claims description 3
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 claims 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 claims 1
- 229940095074 cyclic amp Drugs 0.000 claims 1
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 208000002296 eclampsia Diseases 0.000 description 7
- 210000002381 plasma Anatomy 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000035935 pregnancy Effects 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 208000007530 Essential hypertension Diseases 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 210000002565 arteriole Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 201000001474 proteinuria Diseases 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- YKFCISHFRZHKHY-NGQGLHOPSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid;trihydrate Chemical compound O.O.O.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 YKFCISHFRZHKHY-NGQGLHOPSA-N 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 206010001580 Albuminuria Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000001362 Fetal Growth Retardation Diseases 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000007435 diagnostic evaluation Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 208000030941 fetal growth restriction Diseases 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000001452 natriuretic effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000009822 protein phosphorylation Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5302—Apparatus specially adapted for immunological test procedures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9453—Cardioregulators, e.g. antihypotensives, antiarrhythmics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
- G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44473003P | 2003-02-04 | 2003-02-04 | |
| US60/444,730 | 2003-02-04 | ||
| PCT/US2004/002802 WO2004071273A2 (en) | 2003-02-04 | 2004-02-02 | Method of employing elevation of marinobufagenin in determining the presence of preeclampsia and related apparatus |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU2004210650A1 AU2004210650A1 (en) | 2004-08-26 |
| AU2004210650B2 AU2004210650B2 (en) | 2009-07-30 |
| AU2004210650C1 true AU2004210650C1 (en) | 2010-01-14 |
Family
ID=32869296
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2004210650A Ceased AU2004210650C1 (en) | 2003-02-04 | 2004-02-02 | Method of employing elevation of marinobufagenin in determining the presence of preeclampsia and related apparatus |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7439071B2 (https=) |
| EP (1) | EP1592967A4 (https=) |
| JP (1) | JP4625800B2 (https=) |
| AU (1) | AU2004210650C1 (https=) |
| BR (1) | BRPI0407213A (https=) |
| CA (1) | CA2515012A1 (https=) |
| WO (1) | WO2004071273A2 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7794716B2 (en) | 2002-07-25 | 2010-09-14 | Glenveigh Pharmaceuticals, Llc | Antibody composition and passive immunization against pregnancy-induced hypertension |
| US7402313B2 (en) | 2002-07-25 | 2008-07-22 | Charles David Adair | Method for controlling preeclampsia and eclampsia |
| ATE537823T1 (de) * | 2004-10-19 | 2012-01-15 | Univ Tulane | Verfahren zur behandlung von präeklampsie beim menschen mit resibufagenin |
| US8038997B2 (en) | 2005-06-27 | 2011-10-18 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Anti-marinobufagenin antibodies and methods for their use |
| US20070257366A1 (en) * | 2006-05-03 | 2007-11-08 | Taiwan Semiconductor Manufacturing Company, Ltd. | Barrier layer for semiconductor interconnect structure |
| US20080299602A1 (en) * | 2007-05-31 | 2008-12-04 | Puschett Jules B | Methods of Employing Vascular Leakage to Diagnose a Capillary Leak Disorder |
| WO2010104646A1 (en) * | 2009-03-09 | 2010-09-16 | Scott and White Memorial Hospital | Method of testing a patient for hypertension and related method of treatment and test kit |
| US20110008904A1 (en) * | 2009-07-10 | 2011-01-13 | Scott And White Memorial Hospital And Scott, Sherwood, And Brindley Foundation | Method for determining if a patient has a traumatic brain injury and related apparatus |
| US20110207154A1 (en) * | 2010-01-12 | 2011-08-25 | Scott & White Healthcare | Method for determination of marinobufagenin levels and compounds employable in such method |
| US20160299130A1 (en) * | 2015-04-09 | 2016-10-13 | Jules B. Puschett | Telocinobufagin (TCINO) in the Diagnosis and Pathogenesis of Preeclampsia, Traumatic Brain Injury and Acute Respiratory Distress Syndrome |
| EP3813879A1 (en) | 2018-06-21 | 2021-05-05 | CTS Biopharma LLC | Anti-marinobufagenin antibodies and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5079171A (en) * | 1988-09-15 | 1992-01-07 | Adeza Biomedical Corporation | Determining pregnancy induced hypertension and eclampsia by immunoassay of cellular fibronectin |
| WO1990007122A1 (en) * | 1988-12-14 | 1990-06-28 | The Regents Of The University Of California | Diagnostic assay for the detection of preeclampsia |
| GB9213934D0 (en) * | 1992-06-30 | 1992-08-12 | Smithkline Beecham Corp | Chemical compounds |
| US5770376A (en) * | 1992-12-02 | 1998-06-23 | Biomedical Sciences Research Laboratories, Inc. | Method of diagnosing and treating myocardial infarction and hypertension |
| WO1994012210A1 (en) | 1992-12-02 | 1994-06-09 | Bagrov Alexei Y | Anti-edlf antibody, composition thereof and method of diagnosing and treating cardiac arrhythmias, hypertension |
| US5543138A (en) * | 1994-03-10 | 1996-08-06 | Genetics Institute, Inc. | Methods of diagnosing and treating preeclampsia |
| GB9618931D0 (en) * | 1996-09-11 | 1996-10-23 | Univ London | Inositol phosphoglycans for therapeutic use in pre-eclampsia and diabetes |
| US20030044856A1 (en) * | 1997-09-26 | 2003-03-06 | Puschett Jules B. | Method of determining volume dependent hypertension through protein reduction in phosphorylation or concentration and related apparatus |
| JPH11271222A (ja) * | 1998-03-24 | 1999-10-05 | Sekisui Chem Co Ltd | 尿検査方法 |
| US7794716B2 (en) * | 2002-07-25 | 2010-09-14 | Glenveigh Pharmaceuticals, Llc | Antibody composition and passive immunization against pregnancy-induced hypertension |
| US10167609B1 (en) | 2018-01-12 | 2019-01-01 | Cashman Dredging & Marine Contracting Co., LLC | Carouseling articulated dredge and barge |
-
2004
- 2004-02-02 CA CA002515012A patent/CA2515012A1/en not_active Abandoned
- 2004-02-02 AU AU2004210650A patent/AU2004210650C1/en not_active Ceased
- 2004-02-02 EP EP04707392A patent/EP1592967A4/en not_active Withdrawn
- 2004-02-02 JP JP2006503224A patent/JP4625800B2/ja not_active Expired - Fee Related
- 2004-02-02 BR BR0407213-8A patent/BRPI0407213A/pt not_active IP Right Cessation
- 2004-02-02 US US10/544,468 patent/US7439071B2/en not_active Expired - Fee Related
- 2004-02-02 WO PCT/US2004/002802 patent/WO2004071273A2/en not_active Ceased
Non-Patent Citations (1)
| Title |
|---|
| BAGROV A Y ET Al: "Characterization of a urinary bufodienolide Na+,K+ATPase inhibitor in patients after acute myocardial infarction." HYPERTENSION MAY 1998, vol. 31, no. 5, May 1998 (1998-05), pages 1097-1103 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2006517670A (ja) | 2006-07-27 |
| WO2004071273A2 (en) | 2004-08-26 |
| WO2004071273A3 (en) | 2005-02-03 |
| BRPI0407213A (pt) | 2006-02-07 |
| EP1592967A4 (en) | 2007-06-20 |
| EP1592967A2 (en) | 2005-11-09 |
| AU2004210650A1 (en) | 2004-08-26 |
| AU2004210650B2 (en) | 2009-07-30 |
| US20060263891A1 (en) | 2006-11-23 |
| CA2515012A1 (en) | 2004-08-26 |
| JP4625800B2 (ja) | 2011-02-02 |
| US7439071B2 (en) | 2008-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rana et al. | Ouabain inhibits placental sFlt1 production by repressing HSP27-dependent HIF-1α pathway | |
| Speer et al. | Elevated asymmetric dimethylarginine concentrations precede clinical preeclampsia, but not pregnancies with small-for-gestational-age infants | |
| AU2004210650C1 (en) | Method of employing elevation of marinobufagenin in determining the presence of preeclampsia and related apparatus | |
| Stevenson | Physiological predictors of ovulation and pregnancy risk in a fixed-time artificial insemination program | |
| Yagi et al. | Ibudilast inhibits cerebral aneurysms by down-regulating inflammation-related molecules in the vascular wall of rats | |
| Ye et al. | Apelin/APJ system protects placental trophoblasts from hypoxia-induced oxidative stress through activating PI3K/Akt signaling pathway in preeclampsia | |
| Kurtoglu et al. | Role of vascular endothelial growth factor and placental growth factor expression on placenta structure in pre‐eclamptic pregnancy | |
| US8080539B2 (en) | Method of treating human preeclampsia employing resibufagenin | |
| Royakkers et al. | Serum cystatin CA useful endogenous marker of renal function in intensive care unit patients at risk for or with acute renal failure? | |
| Awad et al. | Intracellular and extracellular expression of the major inducible 70kDa heat shock protein in experimental ischemia-reperfusion injury of the spinal cord | |
| Ambad et al. | The role of serum urea, creatinine, uric acid in diagnosis of pre-eclampsia and eclampsia | |
| Regal et al. | Interactions between the complement and endothelin systems in normal pregnancy and following placental ischemia | |
| Lin et al. | The value of serum uric acid in predicting adverse pregnancy outcomes of women with hypertensive disorders of pregnancy | |
| McMichael et al. | Concentrations of 15F2t isoprostane in urine of dogs with intervertebral disk disease | |
| US7858604B2 (en) | Method of treating human volume expansion mediated hypertension employing resibufogenin | |
| Haeger | The role of complement in pregnancy‐induced hypertensive disease | |
| Dias et al. | A reproducible venous thrombosis model in horses induced by the combination of an endothelial lesion and blood flow stasis | |
| US20080299602A1 (en) | Methods of Employing Vascular Leakage to Diagnose a Capillary Leak Disorder | |
| Parveen et al. | Risk of pre-eclampsia in women with low serum ionized magnesium | |
| Henzel et al. | Systemic vascular reactivity in an aortic coarctation model of preeclampsia in the rat | |
| AL-Hamdani | Physiological Effect of Pregnancy on Some Renal Function Tests | |
| Moritz et al. | Barker and Brenner: a basis for hypertension? | |
| Webb et al. | Targeting Protease-activated Receptor 4 (PAR4) Protects Against Acute Kidney Injury (AKI) in Ischemia Reperfusion Injury | |
| Leaver et al. | Critical appraisal of medical and dietary treatments of proteinuria in dogs and cats. | |
| Du et al. | Once delayed non-invasive remote ischemic preconditioning protects against early stroke by modulating neuroinflammatory responses in rats |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA2 | Applications for amendment section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 17 AUG 2009. |
|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 17 AUG 2009 |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |